Active Ingredient(s): Tucatinib
FDA Approved: * April 17, 2020
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tukysa Overview

Tucatinib, sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer.[4][5] It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics).[6] Common side effects are diarrhea, palmar-plantar erythrodysesthesia (burning or tingling discomfort in the hands and feet), nausea, fatigue, hepatotoxicity (liver damage...

Read more Tukysa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tucatinib

Recent Tukysa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 150mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tukysa: (2 results)

Sorted by National Drug Code
  • 51144-001 Tukysa 50 mg Oral Tablet by Seattle Genetics, Inc.
  • 51144-002 Tukysa 150 mg Oral Tablet by Seattle Genetics, Inc.

Other drugs which contain Tucatinib or a similar ingredient: (1 result)